SPY436.25+2.21 0.51%
DIA341.92+2.52 0.74%
IXIC14,783.56+69.66 0.47%

BRIEF-Xeris Pharmaceuticals Completes Enrollment Of Phase 1 Study Of Levothyroxine

reuters.com · 09/01/2021 07:43
BRIEF-Xeris Pharmaceuticals Completes Enrollment Of Phase 1 Study Of Levothyroxine

- Xeris Pharmaceuticals Inc XERS:

  • XERIS PHARMACEUTICALS COMPLETES ENROLLMENT OF ITS PHASE 1 STUDY OF LEVOTHYROXINE (XP-8121)

  • XERIS PHARMACEUTICALS - PRELIMINARY RESULTS ANTICIPATED IN Q1 2022 FOR PHASE 1 STUDY OF LEVOTHYROXINE (XP-8121)

Source text for Eikon: ID:nBw9VHt8Ta

Further company coverage: XERS


((Reuters.Briefs@thomsonreuters.com;))